Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10

Blood

Volumn 98, Issue 10, 2001, Pages 2992-2998

  Brown, Ross D ^a,b   Pope, Belinda ^a,b   Murray, Allan ^a,b   Esdale, Warren ^a,b   Sze, Daniel M ^a,b   Gibson, John ^a,b   Joy Ho, P ^a,b   Hart, Derek ^a,b   Joshua, Doug ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CYTOKINE; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONOCYTE; MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 0035892109     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.2992     Document Type: Article

References (36)

1. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991;173:721-730.
2. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumour immunity. Blood. 1994;84:3261-3282.
3. Schultz J, Nadler L, Gribben J. B7-mediated co-stimulation and the immune response. Blood Rev. 1996;10:111-127.
4. Macatonia SE, Lau R, Patterson S, Pinching AJ, Knight SC. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology. 1990;71:38-45.
5. Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH, Hart DN. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood. 1999;93:728-736.
6. Hart DNJ. DC: unique leukocyte populations which control the primary immune reponse. Blood. 1997;90:3245-3287.
7. Zinneman HH, Hall WH. Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann Intern Med. 1954;41:1152-1170.
8. Joshua DE, Brown G, MacLennan IC. Immune suppression in BALB/c mice bearing the plasmacytoma TEPC-183: evidence for normal lymphocyte but defective macrophage function. Int J Cancer. 1979;23:663-772.
9. Raje N, Gong J, Chauhan D, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999;93:1487-1495.
10. Pfeiffer S, Gooding RP, Apperley JF, et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol. 1997;98:973-982.
11. Massala M, Borrlone P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94:673-683.
12. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood. 1999;93:2411-2419.
13. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-963.
14. Dabadghao S, Bergenbrant S, Anton D, et al. Antiidiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol. 1998;100:647-654.
15. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother. 1997;20:165-177.
16. + T cells. J Exp Med. 1996;184:19-29.
17. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925-935.
18. Brossart P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 2000;60:4485-4492.
19. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159:4772-4780.
20. Brown RD, Joshua DE, Ioannidis RA, Kronenberg H. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Aust N Z J Med. 1989;19:226-232.
21. Joshua DE, Penny R, Matthews JP, et al. Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without Interferon in patients with myeloma. Br J Haematol. 1997;97:38-45.
22. Pope B, Brown R, Gibson J, Joshua D. Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Bone Marrow Transplant. 1997;20:205-210.
23. Rettig MB, Ma HJ, Verscio RA, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 1997;276:1851-1854.
24. + cells from multiple myeloma patients. Br J Haematol. 1999;106:1033-1036.
25. Bellos F, Goldschmidt H, Dorner M, Ho AD, Moos M. Bone marrow-derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA. Ann Oncol. 1999;10:323-327.
26. Corbellino M, Pizzuto M, Bestetti G, et al. Absence of Kaposi's sarcoma-associated herpesvirus DNA sequences in multiple myeloma [letter]. Blood. 1999;93:1110-1111.
27. Martin-Fontecha A, Moro A, Crosti MC, et al. Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of anti-tumor immunity. J Immunol. 2000;164:698-704.
28. Blay JY, Burdin F, Rousset G, et al. Serum IL-10 in Non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993;82:2169-2174.
29. Kopper LA, Ladanyi, Mihalik R, Nagy P. Loss of transforming growth factor beta 1 regulatory activity in human non Hodgkin lymphomas. Anticancer Res. 1994;14:119-122.
30. Bost KL, Bieligk SC, Jaffe BM. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies: tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol. 1995;154:718-729.
31. Campbell JDM, Cook G, Carr C, Franklin IM. TGFβ from multiple myeloma cells inhibits activation and IL-2 responses in T lymphocytes [abstract]. Blood. 1998;92(suppl 1):716.
32. Brown RD, Pope B, Yuen E, Gibson J, Joshua DE. The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma. 1998;31:379-384.
33. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med. 1998;188:1849-1857.
34. Maeda H, Shiraishi AAD. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol. 1996;156:73-78.
35. Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun. 1989;158:817-823.
36. Lee PP, Yee C, Savage, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;6:677-685.